| scholarly article | Q13442814 |
| P50 | author | Yeul Hong Kim | Q98617374 |
| Hyun Cheol Chung | Q59647646 | ||
| Jae Yong Cho | Q59684302 | ||
| Kazuhiro Yoshida | Q88970810 | ||
| Hoon-Kyo Kim | Q95983622 | ||
| P2093 | author name string | Mikito Inokuchi | |
| Taroh Satoh | |||
| Masashi Fujii | |||
| Kyung Hee Lee | |||
| Kazuaki Tanabe | |||
| Wasaburo Koizumi | |||
| Hiroshi Imamura | |||
| Mariko Ogura | |||
| Tatsuya Okuno | |||
| Toshifusa Nakajima | |||
| Akihito Tsuji | |||
| Takuo Hara | |||
| Masahiro Takeuchi | |||
| Akinori Takagane | |||
| Hisashi Hosaka | |||
| JACCRO and KCSG Study Group | |||
| P2860 | cites work | Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 |
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. | Q54071888 | ||
| Cisplatin nephrotoxicity | Q69493624 | ||
| A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer | Q73269105 | ||
| Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group | Q73676552 | ||
| [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)] | Q74654940 | ||
| Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients | Q77809280 | ||
| Cisplatin nephrotoxicity | Q78761584 | ||
| Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial | Q80693786 | ||
| Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer | Q83895070 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 | ||
| Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group | Q33348775 | ||
| Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial | Q33658659 | ||
| Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results | Q34524041 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research | Q34581504 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution | Q34635141 | ||
| Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) | Q34669648 | ||
| American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. | Q36485520 | ||
| Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer | Q36614394 | ||
| Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas | Q40022137 | ||
| Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
| Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial | Q40616254 | ||
| Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. | Q40667282 | ||
| Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial | Q42285544 | ||
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 | ||
| Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial | Q44153194 | ||
| Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer | Q46932585 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | platinum | Q880 |
| patient | Q181600 | ||
| docetaxel | Q420436 | ||
| P304 | page(s) | 319-328 | |
| P577 | publication date | 2013-12-24 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). | |
| P478 | volume | 140 |
| Q41617745 | 5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine |
| Q49194716 | A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine |
| Q37004336 | A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy |
| Q37410030 | A case report of curative distal gastrectomy for stage IV gastric cancer after chemoradiotherapy in a patient with a gastrojejunal gastric bypass |
| Q35996020 | A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients |
| Q48327644 | A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). |
| Q87073410 | A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival |
| Q99240998 | Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study |
| Q26764934 | Advanced gastric cancer: Current treatment landscape and future perspectives |
| Q33433129 | Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis |
| Q42135178 | Case of pseudo-Meigs' syndrome caused by gastric cancer-related metastatic ovarian tumor with prolonged survival |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q98779253 | Circular RNA circ_0026359 Enhances Cisplatin Resistance in Gastric Cancer via Targeting miR-1200/POLD4 Pathway |
| Q26765314 | Clinical modalities for management of gastric cancer hepatic metastasis |
| Q89980523 | Combination versus single-agent as palliative chemotherapy for gastric cancer |
| Q91587408 | Conversion Surgery for Stage IV Gastric Cancer |
| Q59335006 | Conversion surgery for gastric cancer patients: A review |
| Q89953581 | Conversion therapy for stage IV gastric cancer-the present and future |
| Q64108800 | Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial |
| Q48052472 | Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial |
| Q33889328 | Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis |
| Q33902814 | Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis |
| Q59810787 | Estimating the Net Survival of Patients with Gastric Cancer in Iran in a Relative Survival Framework |
| Q89908197 | Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review |
| Q92716624 | Interleukin-8 associated with chemosensitivity and poor chemotherapeutic response to gastric cancer |
| Q38800565 | Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis |
| Q28084888 | Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification |
| Q39656427 | Japanese gastric cancer treatment guidelines 2014 (ver. 4). |
| Q89724644 | Japanese gastric cancer treatment guidelines 2018 (5th edition) |
| Q36824887 | Lauren classification and individualized chemotherapy in gastric cancer |
| Q38647893 | Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry |
| Q37701789 | Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer |
| Q41423472 | Long-term survival with complete remission after hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer: a case report |
| Q33425150 | Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma |
| Q38687532 | Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone |
| Q47285124 | Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis |
| Q53560105 | Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer. |
| Q47402625 | Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. |
| Q89745960 | Pathophysiological properties of CLIC3 chloride channel in human gastric cancer cells |
| Q64124471 | Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial |
| Q57035043 | Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer |
| Q86646645 | Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701) |
| Q41643156 | Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). |
| Q48194003 | Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer. |
| Q36396339 | Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. |
| Q49348813 | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial |
| Q54942451 | S-1 Doublet Therapy is the Standard of Care (East). |
| Q38660442 | S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial |
| Q26778027 | Second-line treatment of metastatic gastric cancer: Current options and future directions |
| Q47178340 | Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy |
| Q64246122 | Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis |
| Q41644087 | Systemic chemotherapy as a main strategy for liver metastases from gastric cancer |
| Q38941416 | The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis |
| Q46207048 | The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios. |
| Q90053624 | The Use of (Network) Meta-Analysis in Clinical Oncology |
| Q60961885 | The clinical outcomes of S-1 plus cisplatin for patients with advanced gastric cancer: A meta-analysis and systematic review |
| Q27318805 | The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis |
| Q57055291 | The inhibition of thymidine phosphorylase can reverse acquire 5FU resistance in gastric cancer cells |
| Q47345549 | The long-term survival of stage IV gastric cancer patients with conversion therapy |
| Q92777493 | The prognostic role of platelet-to-lymphocyte ratio on overall survival in gastric cancer: a systematic review and meta-analysis |
| Q50650462 | The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy |
| Q38497265 | Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. |
| Q53458026 | Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. |
| Q55319053 | miRNA-103a-3p Promotes Human Gastric Cancer Cell Proliferation by Targeting and Suppressing ATF7 in vitro. |
| Q48112488 | miRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322. |
Search more.